Status:
UNKNOWN
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Lead Sponsor:
Sherief Abd-Elsalam
Conditions:
Hepatitis C
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
Detailed Description
Impact of Serum Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C
Eligibility Criteria
Inclusion
- HCV patients who will undergo treatment by direct acting antiviral agents.
Exclusion
- Patients with decompensated liver disease
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT03402165
Start Date
January 1 2017
End Date
December 30 2022
Last Update
August 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Tanta, Egypt